Job growth is one byproduct of the billions of biopharma investment dollars that flowed into Massachusetts over the past decade. In just the first half of 2019, Bay State drug companies took in almost $1.5 billion in venture capital and more than $800 million from initial public offerings.
Most of the investments are heading to one specific location: Cambridge, Massachusetts, considered to be the country's preeminent biotech hub.
